The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Every compound added to a stack should contribute something that the others cannot. KPV's addition to GLOW is justified if — and only if — it addresses a dimension of tissue repair that GHK-Cu, BPC-157, and TB-500 do not adequately cover.
The GLOW Stack (GHK-Cu + BPC-157 + TB-500) addresses: local angiogenesis and growth factor signaling at injury sites (BPC-157); systemic progenitor and endothelial cell recruitment (TB-500); ECM remodeling, collagen quality, and gene expression via copper-mediated signaling (GHK-Cu). These three mechanisms collectively address the structural and cellular dimensions of healing comprehensively.
What GLOW does not primarily address: the inflammatory signaling cascade driving chronic inflammation, mast cell hyperactivity (particularly relevant in IBS, allergic conditions, and inflammatory gut pathology), direct COX-2-mediated prostaglandin production, and gut mucosal immune cell (macrophage, epithelial cell) NF-kB activation. BPC-157 has anti-inflammatory effects via its NF-kB suppression and nitric oxide pathway, but it is not a dedicated anti-inflammatory compound. GHK-Cu modulates inflammatory gene expression across >1,500 genes including anti-inflammatory patterns, but its primary mechanism is ECM remodeling. TB-500 suppresses NF-kB systemically but secondarily to its cell migration role.
KPV (Lys-Pro-Val) is a dedicated anti-inflammatory tripeptide. It directly suppresses NF-kB in intestinal epithelial cells and intestinal macrophages, inhibits COX-2 (reducing prostaglandin-driven inflammation), stabilizes mast cells (reducing histamine-mediated inflammatory amplification), and reduces pro-inflammatory cytokines (IL-6, IL-1β, TNF-α). These mechanisms are non-overlapping with GLOW's three components — KPV specifically addresses what GLOW leaves partially uncovered.
THE CENTRAL TENSION
KLOW is mechanistically the most comprehensive tissue repair protocol in this book — four non-overlapping mechanisms covering angiogenesis, cell migration, ECM remodeling, and inflammatory suppression simultaneously. The tension: comprehensiveness is not the same as superiority. Adding a fourth compound means: more injections (or more complex blended vial formulation); more copper accumulation risk on extended cycles (GHK-Cu); more cost; and more moving parts when something doesn't work as expected. For many users, GLOW already covers their needs; KLOW is the right choice when the inflammatory dimension or gut protection is a specific priority. The chapter exists to clarify when KLOW is worth the additional complexity.
Component
Dose
Timing
Notes
GHK-Cu (injectable)
1 mg/day days 1-15; 2 mg/day days 16-30
Evening SubQ abdomen
3mL/50mg reconstitution (Anela standard); copper monitoring q8 weeks
BPC-157
250-500 mcg/day SubQ
Daily; near injury for musculoskeletal
Oral for gut-specific; SubQ for systemic
TB-500 (LKKTETQ)
Loading: 5-10 mg/week × 4 weeks; maintenance: 2-5 mg/week
Twice weekly SubQ anywhere
Systemic mechanism; injection site irrelevant
KPV
500 mcg - 1 mg/day
Oral (enteric-coated) or SubQ
Oral preferred for gut-specific; SubQ for systemic anti-inflammatory
No standard commercial KLOW blend exists at the time of writing the way 70mg GLOW vials do. Users combining all four typically use the GLOW 70mg blend (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) for the injectable components, then add KPV separately oral or SubQ. This preserves the convenience of the GLOW blend while allowing independent KPV dose control and route optimization (oral KPV for gut; SubQ for systemic). The KPV can be in a separate 50-100mg vial reconstituted independently.
Minimum cycle: 8 weeks (same as GLOW; required to capture GHK-Cu's collagen remodeling timeline). Rest: 30+ days. KPV can be cycled continuously with BPC-157 for gut health during the rest period (the Gut Stack remains while GHK-Cu and TB-500 are on rest). Copper monitoring: serum copper and ceruloplasmin at baseline and week 8 (same requirement as GLOW; no change from adding KPV). Active malignancy monitoring: hard stop before starting and any time cancer concern arises during cycle.
Component
Role in KLOW
Dose
Key Safety
Chapter
GHK-Cu (injectable)
ECM remodeling: MMP/TIMP balance, collagen/elastin quality, >1,500 gene modulation; systemic healing enhancement
C (animal systemic); E (community injectable)
1-2 mg/day SubQ (Anela Protocol)
Active malignancy: HARD STOP. Wilson disease: absolute contraindication. Copper monitoring q8 weeks on extended cycles.
pbghkcuinj_v4
BPC-157
Local angiogenesis: VEGF upregulation, GHR expression, FAK fibroblast migration; gut protection
C (animal); E (community)
250-500 mcg/day SubQ
Active malignancy: caution. FDA Category 1 (compounding restricted).
pb002bpc157v4
TB-500 (LKKTETQ)
Systemic cell mobilization: actin polymerization, progenitor/endothelial trafficking; NF-kB
C (full Tβ4 animal); E (fragment community)
Loading 5-10 mg/week × 4 weeks; maintenance 2-5 mg/week
Active malignancy: caution.
pb003tb500v4
KPV
Anti-inflammatory: NF-kB ↓ (intestinal epithelial cells and macrophages); COX-2 ↓; mast cell stabilization; cytokine ↓ (IL-6, IL-1β, TNF-α); gut mucosal protection
C (animal IBD models; Kannengiesser 2008)
500 mcg - 1 mg/day oral or SubQ
No specific cancer concern. No melanocortin activity.
pb027kpv_v4
Healing Dimension
GHK-Cu
BPC-157
TB-500
KPV
KLOW Coverage
Local angiogenesis
Yes (VEGF, systemic)
Yes (VEGF, local, primary mechanism)
Moderate (endothelial migration)
None
Strong — BPC-157 + GHK-Cu dual angiogenic signal
Systemic cell recruitment
Yes (systemic healing signal, animal)
Partial (local FAK migration)
Yes (primary mechanism — actin, progenitor mobilization)
None
Strong — TB-500 primary + GHK-Cu systemic support
ECM remodeling (collagen quality)
Yes (primary — MMP/TIMP, organized collagen)
Partial (fibroblast collagen deposition)
Partial (cell delivery for ongoing synthesis)
None
Strong — GHK-Cu dominates, BPC-157 + TB-500 support
NF-kB anti-inflammatory
Partial (gene expression layer)
Yes (local NF-kB suppression)
Yes (systemic NF-kB)
Yes (primary — direct intestinal epithelial/macrophage NF-kB)
Strong — all four contribute from different directions
COX-2 / prostaglandin inhibition
Partial (gene expression)
Some (NO pathway)
Minimal
Yes (primary COX-2 ↓)
KPV adds this that GLOW doesn’t specifically cover
Mast cell stabilization
None
None
None
Yes (primary)
ONLY from KPV — the key KLOW-specific addition
Cytokine reduction (IL-6, IL-1β, TNF-α)
Partial (gene expression)
Partial (local)
Partial (systemic)
Yes (primary)
KPV significantly strengthens this dimension
Gut mucosal protection
None (injectable; no gut-specific)
Yes (VEGF, tight junctions, mucosal cells)
None
Yes (NF-kB in gut immune cells; mast cells)
BPC-157 + KPV = Gut Stack within KLOW
KLOW is not universally superior to GLOW. It is the right choice when the inflammatory dimension or gut protection is a specific priority alongside healing and ECM remodeling.
Pure musculoskeletal healing without gut/inflammatory focus; cost constraints (KPV adds another compound's cost); simplicity preference for the 8-12 week cycle; no specific mast cell, gut, or inflammatory dimension to the clinical picture. GLOW + the Gut Stack in separate cycles may be a better approach than KLOW blended for users who want to target gut and healing separately.
KLOW is the most expensive stack in this book for a full cycle. Approximate per-cycle (8 weeks) research-grade costs: GLOW blend (70mg vials × 2-3) = $200-350; KPV separately (50-100mg vial) = $30-60; total KLOW = $230-410 research grade. Clinic prices $600-1500+. Whether the KPV addition justifies the extra cost depends entirely on whether the specific anti-inflammatory or gut dimension is a priority for the individual user. For pure musculoskeletal healing without inflammatory or gut concerns, GLOW at lower cost is the appropriate choice. KLOW is the right stack for the right indication, not a universal upgrade.
ACTIVE MALIGNANCY — HARD STOP FOR ENTIRE KLOW STACK
GHK-Cu's VEGF angiogenic mechanism is a hard stop for active malignancy. This applies to the entire KLOW Stack. BPC-157 and TB-500 add independent angiogenic and progenitor cell mobilization cautions that reinforce this. KPV does not add a cancer concern but does not reduce the hard stop from the other three. Active malignancy or suspicion of malignancy: do not use KLOW Stack. Physician consultation mandatory for any cancer history.
GHK-Cu carries an absolute contraindication for Wilson disease (copper accumulation disorder). This applies to all stacks containing GHK-Cu, including KLOW. Absolute contraindication.
The 8-12 week KLOW cycle at daily GHK-Cu dosing (1-2 mg/day) accumulates approximately 9-21 mg of copper from GHK-Cu over the cycle. Serum copper and ceruloplasmin at baseline and week 8 is mandatory for extended cycles. Liver function panel (ALT/AST) before starting.
Stack
Relationship to KLOW
When to Use Instead
Wolverine Stack (BPC-157 + TB-500)
3-component subset of KLOW (removes GHK-Cu and KPV)
Pure musculoskeletal healing; 4-week cycles; no cosmetic/inflammatory/gut dimension needed; lower cost
GLOW Stack (GHK-Cu + BPC-157 + TB-500)
3-component subset (removes KPV)
Healing + cosmetic without specific anti-inflammatory or gut focus; 8-12 week cycles
Gut Stack (BPC-157 + KPV)
2-component subset (BPC-157 + KPV; oral; gut-specific)
Gut-only indication; no musculoskeletal healing component; oral route; lower cost and complexity
KLOW Stack (all four)
Full stack
Healing + cosmetic + anti-inflammatory + gut protection simultaneously; highest complexity; longest cycle; highest cost
KLOW adds a fourth compound with real non-overlapping mechanisms. But more compounds means more complexity, more cost, more copper accumulation (same as GLOW), more potential interactions that haven't been studied, and more injection burden. KLOW is superior to GLOW when the KPV anti-inflammatory and gut dimension is specifically relevant. It is not universally superior for all users in all contexts.
No combination study exists for KLOW or any three-way subset of these compounds. The evidence is entirely individual component-level (Grade C animal for each) and community experience. The combination has not been tested in any controlled study at any scale.
KLOW is the most mechanistically complete tissue repair protocol in this book. Use it when that completeness matches a specific clinical picture. Don’t use it just because it’s more.
STACK SUMMARY
KLOW Stack: type=stack; slug=klow-stack; stackGrade=C. COMPONENTS: ghk-cu-injectable + bpc-157 + tb-500 + kpv. relatedStacks: glow-stack (subset), wolverine-stack (3-component subset), gut-stack (BPC-157 + KPV subset). indication: full-spectrum healing + cosmetic tissue rejuvenation + systemic anti-inflammatory + gut protection. studyCounts: humanRct:0, combinationStudies:0; individual components: all Grade C animal. MECHANISM LAYERS: BPC-157 → local angiogenesis (VEGF, GHR, FAK); TB-500 → systemic progenitor/endothelial mobilization (actin polymerization); GHK-Cu → ECM remodeling (MMP/TIMP, collagen/elastin, >1,500 genes); KPV → anti-inflammatory (NF-kB ↓ intestinal immune cells; COX-2 ↓; mast cell stabilization; cytokines ↓ IL-6/IL-1β/TNF-α). WHAT KPV ADDS OVER GLOW: mast cell stabilization (ONLY compound in KLOW/GLOW series with this); direct COX-2 inhibition; gut mucosal immune cell NF-kB suppression (more specific than BPC-157's general NF-kB); cytokine reduction (stronger than GLOW components alone). GUT DIMENSION: BPC-157 (structural gut repair) + KPV (gut inflammatory suppression) = Gut Stack embedded within KLOW. ACTIVE MALIGNANCY: HARD STOP (GHK-Cu angiogenic; same as GLOW; BPC-157 and TB-500 add independent cautions). WILSON DISEASE: absolute contraindication. COPPER MONITORING: baseline + week 8 serum copper/ceruloplasmin; liver panel before starting. PROTOCOL: GLOW blend (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) for injectable; KPV separately oral (gut focus) or SubQ (systemic); 8-12 week minimum cycle; 30+ day rest. COST: ~$230-410 per 8-week cycle research grade. CHOOSE KLOW WHEN: gut + anti-inflammatory + healing + cosmetic all needed simultaneously; mast cell issues; chronic inflammation as primary driver. CHOOSE GLOW INSTEAD: healing + cosmetic without specific inflammatory/gut concern; cost sensitivity; simplicity preference.
— End of KLOW Stack —
THE PEPTIDE BIBLE | KLOW Stack | For Research & Educational Purposes Only
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.